Enigma Diagnostics Ltd.
This article was originally published in Start Up
Executive Summary
The key to combating an infectious disease threat, be it an individual case of Chlamydia or the global threat of bioterrorism or pandemic avian flu, is rapid on-site diagnosis, enabling physicians to treat--or public health professionals to contain--the disease. One solution is the use of the gold standard test for biological agents, real-time polymerase chain reaction testing. Enigma Diagnostics Ltd. says it is the first UK company to take this technique out of the laboratory and into the field.
You may also be interested in...
Start-Up Previews (02/07)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.